Abstract
Berzosertib is a potent inhibitor of ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR). Preclinical studies have shown that ATR inhibition enhances the cytotoxic effects of DNA damaging drugs. Cohort A2 of the CHARIOT trial (NCT03641547) explored the combination of berzosertib with cisplatin and capecitabine in advanced solid tumours to assess the optimal treatment schedule, safety and preliminary efficacy.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call